Trial Profile
Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SALTORL
- 05 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2022 Planned End Date changed from 24 Sep 2028 to 1 Nov 2028.
- 10 Mar 2022 Planned primary completion date changed from 24 Sep 2026 to 1 Oct 2028.